Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists

Abstract

The treatment goal for patients with immune thrombocytopaenia (ITP) is to raise platelet counts to levels that minimize or stop bleeding. Thrombopoietin receptor agonists (TPO-RAs) have been successfully and extensively employed as second-line therapy for ITP. However, TPO-RAs have a small but significant increase in the risk of thrombosis. The aim of this study was to elucidate the mechanisms involved in the pro-coagulant effect of TPO-RAs to take them into account when considering their use in ITP patients with concomitant diseases/conditions that might increase risk of suffering thrombotic events. Eighty-two patients with chronic primary ITP (40 untreated and 42 undergoing TPO-RA therapy) and 112 healthy individuals were recruited. The patients with ITP undergoing TPO-RA therapy presented a pro-coagulant profile due to the formation of a more fibrinolysis-resistant clot because of increased plasminogen activator inhibitor-1 (PAI-1) levels. Increase in platelet content of PAI-1 might be the result of the effect of TPO-RA during megakaryopoiesis, as suggested by experiments performed in MEG-01 cells. Moreover, patients under TPO-RA treatment presented an enhanced pro-coagulant activity associated with microparticles and an increased platelet apoptosis that causes a higher exposure of phosphatidylserine and, consequently, a larger surface for the binding of the prothrombinase complex.

Keywords

immune thrombocytopaenia - platelet apoptosis - PAI-1 - thrombopoietin receptor agonists - platelet function

• References

• 1 Rodeghiero F, Stasi R, Gernsheimer T. , et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11) 2386-2393
• 2 Provan D, Stasi R, Newland AC. , et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115 (02) 168-186
• 3 Frelinger III AL, Grace RF, Gerrits AJ, Carmichael SL, Forde EE, Michelson AD. Platelet function in ITP, independent of platelet count, is consistent over time and is associated with both current and subsequent bleeding severity. Thromb Haemost 2018; 118 (01) 143-151
• 4 Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. J Lab Clin Med 1992; 119 (04) 334-345
• 5 Sewify EM, Sayed D, Abdel Aal RF, Ahmad HM, Abdou MA. Increased circulating red cell microparticles (RMP) and platelet microparticles (PMP) in immune thrombocytopenic purpura. Thromb Res 2013; 131 (02) e59-e63
• 6 Álvarez-Román MT, Fernández-Bello I, Jiménez-Yuste V. , et al. Procoagulant profile in patients with immune thrombocytopenia. Br J Haematol 2016; 175 (05) 925-934
• 7 Norgaard M, Cetin K, Maegbaek ML. , et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol 2016; 174 (04) 639-642
• 8 Doobaree IU, Nandigam R, Bennett D, Newland A, Provan D. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis. Eur J Haematol 2016; 97 (04) 321-330
• 9 Sarpatwari A, Bennett D, Logie JW. , et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research Database. Haematologica 2010; 95 (07) 1167-1175
• 10 Nørgaard M. Thrombosis in patients with primary chronic immune thrombocytopenia. Thromb Res 2012; 130 (Suppl. 01) S74-S75
• 11 Cheng G, Saleh MN, Marcher C. , et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet 2011; 377 (9763): 393-402
• 12 Lakshmanan S, Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost 2012; 10 (10) 1988-1998
• 13 Boyle S, White RH, Brunson A, Wun T. Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. Blood 2013; 121 (23) 4782-4790
• 14 Kuter DJ, Bussel JB, Newland A. , et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol 2013; 161 (03) 411-423
• 15 Catalá-López F, Corrales I, de la Fuente-Honrubia C. , et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc) 2015; 145 (12) 511-519
• 16 McCormack PL. Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs 2015; 75 (05) 525-531
• 17 Qureshi K, Patel S, Meillier A. The use of thrombopoietin receptor agonists for correction of thrombocytopenia prior to elective procedures in chronic liver diseases: review of current evidence. Int J Hepatol 2016; 2016: 1802932
• 18 Guitton Z, Terriou L, Lega JC. , et al. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology (Oxford) 2018; 57 (08) 1432-1438
• 19 Hayashi S, Oshida M, Kiyoi T. , et al. Reticulated platelet determination: methodologies and applications for the evaluation of thrombocytopenic disorders [in Japanese]. Rinsho Ketsueki 1999; 40 (03) 205-212
• 20 Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood 2017; 129 (21) 2829-2835
• 21 Elgebaly AS, Ashal GE, Elfil M, Menshawy A. Tolerability and efficacy of eltrombopag in chronic immune thrombocytopenia: meta-analysis of randomized controlled trials. Clin Appl Thromb Hemost 2017; 23 (08) 928-937
• 22 González-Porras JR, Mingot-Castellano ME, Andrade MM. , et al. Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 2015; 169 (01) 111-116
• 23 Saleh MN, Bussel JB, Cheng G. , et al; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood 2013; 121 (03) 537-545
• 24 Wong RSM, Saleh MN, Khelif A. , et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017; 130 (23) 2527-2536
• 25 Haselboeck J, Kaider A, Pabinger I, Panzer S. Function of eltrombopag-induced platelets compared to platelets from control patients with immune thrombocytopenia. Thromb Haemost 2013; 109 (04) 676-683
• 26 Cines DB, Gernsheimer T, Wasser J. , et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol 2015; 102 (03) 259-270
• 27 Gernsheimer TB, George JN, Aledort LM. , et al. Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with chronic immune thrombocytopenia (ITP). J Thromb Haemost 2010; 8 (06) 1372-1382
• 28 Thai LH, Mahévas M, Roudot-Thoraval F. , et al. Long-term complications of splenectomy in adult immune thrombocytopenia. Medicine (Baltimore) 2016; 95 (48) e5098
• 29 Guthikonda S, Alviar CL, Vaduganathan M. , et al. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52 (09) 743-749
• 30 Diacovo TG, Roth SJ, Buccola JM, Bainton DF, Springer TA. Neutrophil rolling, arrest, and transmigration across activated, surface-adherent platelets via sequential action of P-selectin and the beta 2-integrin CD11b/CD18. Blood 1996; 88 (01) 146-157
• 31 Yanabu M, Nomura S, Fukuroi T. , et al. Platelet activation induced by an antiplatelet autoantibody against CD9 antigen and its inhibition by another autoantibody in immune thrombocytopenic purpura. Br J Haematol 1993; 84 (04) 694-701
• 32 Garabet L, Ghanima W, Monceyron Jonassen C. , et al. Effect of thrombopoietin receptor agonists on markers of coagulation and P-selectin in patients with immune thrombocytopenia. Platelets 2017 Doi:10.1080/09537104.2017.1394451
• 33 Deng G, Yu S, Li Q. , et al. Investigation of platelet apoptosis in adult patients with chronic immune thrombocytopenia. Hematology 2017; 22 (03) 155-161
• 34 Erwig LP, Henson PM. Clearance of apoptotic cells by phagocytes. Cell Death Differ 2008; 15 (02) 243-250
• 35 Savill J, Fadok V. Corpse clearance defines the meaning of cell death. Nature 2000; 407 (6805): 784-788
• 36 Mitchell WB, Pinheiro MP, Boulad N. , et al. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Am J Hematol 2014; 89 (12) E228-E234
• 37 Goette NP, Glembotsky AC, Lev PR. , et al. Platelet apoptosis in adult immune thrombocytopenia: insights into the mechanism of damage triggered by auto-antibodies. PLoS One 2016; 11 (08) e0160563
• 38 Fager AM, Wood JP, Bouchard BA, Feng P, Tracy PB. Properties of procoagulant platelets: defining and characterizing the subpopulation binding a functional prothrombinase. Arterioscler Thromb Vasc Biol 2010; 30 (12) 2400-2407
• 39 Lopez JJ, Palazzo A, Chaabane C. , et al. Crucial role for endoplasmic reticulum stress during megakaryocyte maturation. Arterioscler Thromb Vasc Biol 2013; 33 (12) 2750-2758
• 40 López E, Berna-Erro A, López JJ. , et al. Role of mTOR1 and mTOR2 complexes in MEG-01 cell physiology. Thromb Haemost 2015; 114 (05) 969-981
• 41 Booth NA, Robbie LA, Croll AM, Bennett B. Lysis of platelet-rich thrombi: the role of PAI-1. Ann N Y Acad Sci 1992; 667: 70-80
• 42 Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood 2004; 104 (13) 3943-3948
• 43 Madoiwa S, Komatsu N, Mimuro J, Kimura K, Matsuda M, Sakata Y. Developmental expression of plasminogen activator inhibitor-1 associated with thrombopoietin-dependent megakaryocytic differentiation. Blood 1999; 94 (02) 475-482